[125I]iodotamoxifen cytotoxicity in cultured human (MCF-7) breast cancer cells.
We evaluated the uptake and radiotoxicity of [125I]iodotamoxifen (125ITAM) in MCF-7 human breast cancer cells in the presence or absence of excess non-radioactive estradiol (E2) or iodotamoxifen (ITAM). Studies in cells under wash-out conditions and in nuclei isolated from previously exposed cells showed that 125ITAM binds estrogen receptor (ER) and antiestrogen binding sites (AEBS) and has the capacity for considerable non-specific binding. The radiotoxicity of 125ITAM was a complex function related to ER content and/or function as well as interactions with ER, AEBS and non-specific binding. Addition of E2 or ITAM abolished ER mediated cell killing. ITAM but not E2 abolished AEBS mediated cytotoxicity. Non-specific binding accounted for considerable cytotoxicity. Although these studies confirm the radiotoxicity of nuclear bound 125I, multiple nuclear binding sites, variability in ER content and function and non-specific binding will all adversely influence ultimate clinical efficacy.
McLaughlin
W H
WH
Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York.
Pillai
K M
KM
Edasery
J P
JP
Blumenthal
R D
RD
Bloomer
W D
WD
D001943:Breast Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D011960:Receptors, Estrogen / Q000378:metabolism; D013629:Tamoxifen / Q000493:pharmacokinetics / Q000031:analogs & derivatives; D014407:Tumor Cells, Cultured / Q000378:metabolism / Q000528:radiation effects
D007457:Iodine Radioisotopes; D011960:Receptors, Estrogen; D013629:Tamoxifen; C035179:iodotamoxifen